The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07552779 |
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir |
COMPLETED | PHASE1 |
